AstraZeneca Bets on AI for Cancer Treatments
Pharmaceutical giant AstraZeneca signed a $247 million deal with biotech firm Absci, specializing in AI-driven drug development. This partnership aims to innovate cancer treatment methods.
On this page
Pharmaceutical giant AstraZeneca signed a $247 million deal with biotech
firm Absci, specializing in AI-driven drug development. This
partnership aims to innovate cancer treatment methods.
“We're
proud to work closely with AstraZeneca to leverage our AI to bring
novel treatments to oncology patients,” Absci CEO Sean McClain said.
The
ultimate goal of this collaboration is to develop a generative AI model
capable of proposing new therapies or enhancing existing ones. However,
the specific cancer types targeted in this initiative remain
unspecified.
The content on The Coinomist is for informational purposes only and should not be interpreted as financial advice. While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any content. Neither we accept liability for any errors or omissions in the information provided or for any financial losses incurred as a result of relying on this information. Actions based on this content are at your own risk. Always do your own research and consult a professional. See our Terms, Privacy Policy, and Disclaimers for more details.
Articles by this author
